Dec 23, 2013 | Daniel A. Spyker, PhD, MD, Polina Voloshko, MD, Eugene R. Heyman, PhD, and James V. Cassella, PhD
Loxapine, which was introduced more than 35 years ago in the US, Canada, and Europe, has a well-established efficacy and safety profile in the treatment of schizophrenia. Although it was approved by the FDA, a thorough QT/QTc study had not been conducted for loxapine.
To establish the effects of inhaled loxapine on the QTc interval in a randomized, placebo-controlled, double-blind crossover trial, 48 healthy volunteers received a single inhaled placebo or 10mg loxapine to test the effects.
Download the publication to discover the key findings of the study, including: